FORGE Life Science Head
of Biology, Eain Murphy, presents, “Targeting Host-cell Metabolism to Address
Respiratory Viruses”, at the 6th International Society for Influenza
and Other Respiratory Virus Diseases (ISIRV) Antiviral Group Conference –
Advanced Respiratory Virus Therapeutics, Rockville, MD.
FORGE Life Science is
awarded its first Department of Defense STTR contract (W911QY18P0300) from the
Joint Project Manager Medical Countermeasure Systems. Proposal titled, “Host-Targeted
Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum Medical
Countermeasure Against Marburg Virus”.
FORGE Life Science CEO, Lillian Chiang, presents at the National
Institutes of Health CMV Workshop, Cytomegalovirus Infection: Advancing
Strategies for Prevention and Treatment.
The European Patent Office grants patent EP 2670404 B1, allowing claims
directed to antiviral treatments with inhibitors of two or more sirtuins. This
I.P. is exclusively licensed by FORGE from Princeton University. Read more
Life Science completes its Phase I milestones and receives a Notice of
Award for the Phase II component of its FastTrack SBIR grant titled, “Sirtuin
Agonists as Pan Influenza Antivirals” (4R44AI122488-02). Read more
FORGE Life Science enters into a Sponsored Research Agreement with St.
Jude Children’s Research Hospital. FORGE will collaborate with Drs. Richard J.
Webby and Elena Govorkova to study the effect of FORGE host-targeted antivirals
in ferret models of respiratory infection.
FORGE Life Science enters
into a Cooperative Research & Development Agreement with the U.S. Army
Medical Research Institute of Infectious Disease to test FORGE host-targeted
antivirals against Department of Defense priority pathogens such as Marburg
virus, Venezuelan equine encephalitis virus, and Lassa virus.
FORGE Life Science
President & CEO, Lillian Chiang, is selected to join Springboard
Enterprises Health Innovation Hub 2018: Life Sciences Track cohort for women
entrepreneurs. Read more
FORGE Life Science announces
final close of $6.3 M raised in Series A-1 financing with participation by all
founding investors. The funds will progress FORGE’s novel first-in-class
host-targeted antivirals towards delivering transformational broad-spectrum
treatment modalities to patients in need.
FORGE Life Science President & CEO, Lillian Chiang, presents “Targeting Host-cell Metabolism to Address Multiple Intracellular Pathogens” at the 2017 Chemical and Biological Defense Science & Technology Conference, Long Beach, CA. Read more
FORGE Life Science secures a second in-kind services investment from BioArdis,
LLC, expanding FORGE medicinal chemistry and DMPK research resources to include
BioDuro, global provider of contract research services.
FORGE Life Science Board
of Directors meeting with new external members Richard J. Whitley, Brian Pusch,
Steven Holtzman joining Founders Thomas E. Shenk and Lillian W. Chiang on the
Board.
FORGE Life Science Board
Chairman, Thomas Shenk, presents at China Renaissance’s 4th Healthcare and Life
Sciences Leadership Summit in Shanghai, China.
BioCentury Innovations covers FORGE Life Science. “Sirtuins forge ahead – How FORGE Life Science is targeting sirtuins to treat viral infections.” Read more.
BioCentury Innovations covers FORGE Life Science. “Sirtuins forge ahead – How FORGE Life Science is targeting sirtuins to treat viral infections.” Read more
FORGE Life Science is awarded its fourth grant from the NIH National Institute for Allergy and Infectious Disease titled, ”Sirtuin Agonists as Pan-Influenza Antivirals” (1R44AI122488-01). Read more
FORGE Life Science secures an in-kind services investment from ShangPharma Investment Group Limited providing FORGE medicinal chemistry and DMPK contract research services from the service division of the ShangPharma group, ChemPartner, a leading contract research organization.
FORGE Life Science Board Chairman, Thomas Shenk is keynote speaker at the BioCentury China Healthcare Summit in Shanghai, China. His talk, “Been There, Done That, Doing It Again” tells his personal story as a serial entrepreneur from ImClone Systems to FORGE Life Science.
Dr. Eain Murphy, formerly Associate Professor of Virology at the Cleveland Clinic Lerner Research Institute, joins FORGE Life Science as Head of Biology.
FORGE Life Science is awarded its third grant from the NIH National Institute for Allergy and Infectious Disease titled, “An Antiviral to Treat Progressive Multifocal Leukoencephalopathy (PML)” (1R43AI118232-01). Read more
FORGE Life Science Founders, Ileana Cristea, Emre Koyuncu, and Thomas Shenk publish their breakthrough discovery that “Sirtuins Are Evolutionarily Conserved Viral Restriction Factors”. Read more
Dr. Stacy Remiszewski,
former Director of Chemistry, Section Head for Oncology Chemistry at
Hoffmann-La Roche, joins FORGE Life Science as Head Of Chemistry.
FORGE Life Science LLC is awarded a second grant from the NIH National Institute for Allergy and Infectious Disease titled, “A Single Antiviral to Treat Multiple Opportunistic Infections” (1R43AI114079-01). Read more
FORGE Life Science LLC grant titled, “Host-Targeted Mechanism of Action for Treatment of Seasonal and Pandemic Influenza”, is awarded by the NIH National Institute for Allergy and Infectious Diseases (1R43AI110048-01). Read more
May 29, 2019:
NewsFORGE Life Science is now Evrys Bio. Read more
April 17, 2019:
NewsFORGE Life Science secures $1.0 M in bridge financing from its strategic investors.
November 13, 2018:
NewsFORGE Life Science Head of Biology, Eain Murphy, presents, “Targeting Host-cell Metabolism to Address Respiratory Viruses”, at the 6th International Society for Influenza and Other Respiratory Virus Diseases (ISIRV) Antiviral Group Conference – Advanced Respiratory Virus Therapeutics, Rockville, MD.
September 25, 2018:
NewsFORGE Life Science is awarded its first Department of Defense STTR contract (W911QY18P0300) from the Joint Project Manager Medical Countermeasure Systems. Proposal titled, “Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum Medical Countermeasure Against Marburg Virus”.
September 4, 2018:
NewsFORGE Life Science CEO, Lillian Chiang, presents at the National Institutes of Health CMV Workshop, Cytomegalovirus Infection: Advancing Strategies for Prevention and Treatment.
August 29, 2018:
NewsThe European Patent Office grants patent EP 2670404 B1, allowing claims directed to antiviral treatments with inhibitors of two or more sirtuins. This I.P. is exclusively licensed by FORGE from Princeton University. Read more
August 20, 2018:
NewsFORGE Life Science CEO, Lillian Chiang, presents at the Military Health System Research Symposium, Kissimmee, FL. Read more
August 14, 2018:
NewsLife Science completes its Phase I milestones and receives a Notice of Award for the Phase II component of its FastTrack SBIR grant titled, “Sirtuin Agonists as Pan Influenza Antivirals” (4R44AI122488-02). Read more
July 15, 2018:
NewsFORGE Life Science enters into a Sponsored Research Agreement with St. Jude Children’s Research Hospital. FORGE will collaborate with Drs. Richard J. Webby and Elena Govorkova to study the effect of FORGE host-targeted antivirals in ferret models of respiratory infection.
June 18, 2018:
NewsFORGE Life Science enters into a Cooperative Research & Development Agreement with the U.S. Army Medical Research Institute of Infectious Disease to test FORGE host-targeted antivirals against Department of Defense priority pathogens such as Marburg virus, Venezuelan equine encephalitis virus, and Lassa virus.
April 25, 2018:
NewsFORGE Life Science President & CEO, Lillian Chiang, is selected to join Springboard Enterprises Health Innovation Hub 2018: Life Sciences Track cohort for women entrepreneurs. Read more
February 28, 2018:
NewsFORGE Life Science completes Milestone 1 in agreement with BioArdis, LLC, securing second tranche of in-kind services investment.
December 1, 2017:
NewsFORGE Life Science announces final close of $6.3 M raised in Series A-1 financing with participation by all founding investors. The funds will progress FORGE’s novel first-in-class host-targeted antivirals towards delivering transformational broad-spectrum treatment modalities to patients in need.
November 28, 2017:
NewsFORGE Life Science President & CEO, Lillian Chiang, presents “Targeting Host-cell Metabolism to Address Multiple Intracellular Pathogens” at the 2017 Chemical and Biological Defense Science & Technology Conference, Long Beach, CA. Read more
May 1, 2017:
NewsFORGE Life Science secures a second in-kind services investment from BioArdis, LLC, expanding FORGE medicinal chemistry and DMPK research resources to include BioDuro, global provider of contract research services.
February 21, 2017:
NewsFORGE Life Science Board of Directors meeting with new external members Richard J. Whitley, Brian Pusch, Steven Holtzman joining Founders Thomas E. Shenk and Lillian W. Chiang on the Board.
JANUARY 9-11, 2017:
NewsFORGE Life Science President & CEO, Lillian Chiang, presents at 9th Annual Biotech Showcase 2017 investor conference in San Francisco, CA.
October 27, 2016:
NewsFORGE Life Science Board Chairman, Thomas Shenk, presents at China Renaissance’s 4th Healthcare and Life Sciences Leadership Summit in Shanghai, China.
October 20, 2016:
NewsBioCentury Innovations covers FORGE Life Science. “Sirtuins forge ahead – How FORGE Life Science is targeting sirtuins to treat viral infections.” Read more.
October 20, 2016
NewsBioCentury Innovations covers FORGE Life Science. “Sirtuins forge ahead – How FORGE Life Science is targeting sirtuins to treat viral infections.” Read more
September 20, 2016:
NewsFORGE Life Science named one of 2016’s Best University Startups by the National Council of Entrepreneurial Tech Transfer (NCET2). Read more
August 5, 2016:
NewsFORGE Life Science is awarded its fourth grant from the NIH National Institute for Allergy and Infectious Disease titled, ”Sirtuin Agonists as Pan-Influenza Antivirals” (1R44AI122488-01). Read more
June 27, 2016:
NewsMid Atlantic Bio Angels chooses FORGE Life Science for its first Closed-End Investing Pool investment. Read more
June 1, 2016:
NewsFORGE Life Science secures an in-kind services investment from ShangPharma Investment Group Limited providing FORGE medicinal chemistry and DMPK contract research services from the service division of the ShangPharma group, ChemPartner, a leading contract research organization.
October 19, 2015:
NewsFORGE Life Science Board Chairman, Thomas Shenk is keynote speaker at the BioCentury China Healthcare Summit in Shanghai, China. His talk, “Been There, Done That, Doing It Again” tells his personal story as a serial entrepreneur from ImClone Systems to FORGE Life Science.
August 1, 2015:
NewsDr. Eain Murphy, formerly Associate Professor of Virology at the Cleveland Clinic Lerner Research Institute, joins FORGE Life Science as Head of Biology.
February 5, 2015:
NewsFORGE Life Science is awarded its third grant from the NIH National Institute for Allergy and Infectious Disease titled, “An Antiviral to Treat Progressive Multifocal Leukoencephalopathy (PML)” (1R43AI118232-01). Read more
December 16, 2014:
NewsFORGE Life Science Founders, Ileana Cristea, Emre Koyuncu, and Thomas Shenk publish their breakthrough discovery that “Sirtuins Are Evolutionarily Conserved Viral Restriction Factors”. Read more
October 14, 2014:
NewsFORGE Life Science receives JumpStart Award announced at PA BIO Life Sciences Futures annual meeting in Philadelphia, PA. Read more
September 2014:
NewsFORGE Life Science featured in the Innovator’s Corner of PharmaVoice magazine. Read more
August 1, 2014:
NewsDr. Stacy Remiszewski, former Director of Chemistry, Section Head for Oncology Chemistry at Hoffmann-La Roche, joins FORGE Life Science as Head Of Chemistry.
June 4, 2014:
NewsFORGE Life Science LLC is awarded a second grant from the NIH National Institute for Allergy and Infectious Disease titled, “A Single Antiviral to Treat Multiple Opportunistic Infections” (1R43AI114079-01). Read more
February 5, 2014:
NewsFORGE Life Science LLC grant titled, “Host-Targeted Mechanism of Action for Treatment of Seasonal and Pandemic Influenza”, is awarded by the NIH National Institute for Allergy and Infectious Diseases (1R43AI110048-01). Read more
January 28, 2014:
NewsFORGE Life Science LLC exclusively licenses Sirtuin-Antiviral Technology from Princeton University.
January 14, 2013:
NewsFORGE Life Science LLC leases BSL2+ facilities from the Pennsylvania Biotechnology Center.